NLS Collaboration

The two companies are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms. This collaboration seeks to provide customers and the pharmaceutical industry with new capabilities in patient centric therapies, they state in a press release. The immediate product innovation target for the collaboration is to combine Nanoform’s fast […]

Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and […]

As an example of the versatility of the Nordic life science industry we have chosen to highlight five Nordic stars in our latest issue of the magazine. The five companies are at different stages of development, with different focus areas, from different Nordic countries, and they represent the different strongholds that the region possesses. One […]

The 2021 NLSDays, April 20-23, will be arranged digitally and will include extended time for face-to-face partnering meetings, high-level content sessions, workshops and innovating digital networking features. Since its inception in 2013, Nordic Life Science Days (NLSDays) has grown to become the largest Nordic partnering conference dedicated to the life science industry. This annual event […]

Alligator Bioscience has entered into a joint research collaboration with MacroGenics to develop novel immunotherapy. The research collaboration will lead to the expansion of Alligator’s patient specific immunotherapy Neo-X-Prime by incorporating MacroGenics’ DART and TRIDENT multi-specific platforms against two undisclosed targets, reveals the company in a press release. “The aim is to create a drug […]

Immunicum has announced the initiation of a research collaboration with the laboratory of Nina Bhardwaj, Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core Facility, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City. Dr. Bhardwaj is a leading researcher who has made significant […]